Case Report

Olanzapine-Induced Malignant Neuroleptic Syndrome

10.5152/TJAR.2014.46704

  • Tuba Berra Sarıtaş
  • Barış Çankaya
  • Alper Yosunkaya

Received Date: 12.08.2013 Accepted Date: 08.10.2013 Turk J Anaesthesiol Reanim 2014;42(5):288-291

Neuroleptic malignant syndrome (NMS), caused by antipsychotic therapy, shows itself with mental status alteration, high fever, autonomic dysfunction, and muscle rigidity. It is a rare idiosyncratic reaction with mortality risk. The etiology is still unknown. NMS-related mortality and morbidity can be decreased by cessation of the used drug and aggressive treatment. Olanzapine is a thienobenzodiazepine, a member of atypical antipsychotic drugs; its structure and effects on neurotransmitters resemble clozapine. Here we report a case of bipolar disorder receiving olanzapine therapy for 10 years, who developed NMS without rigidity. We emphasized the importance of early hydration and hemodiafiltration therapy.

Keywords: Neuroleptic malignant syndrome, olanzapine, rigidity, hemodiafiltration